Gene therapy for cancer

European Journal of Cancer

Volumn 35, Issue 6, 1999, Pages 867-885

  Gomez Navarro J ^a   Curiel, D T ^b   Douglas, J T ^c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUOROURACIL; GANCICLOVIR; RADIOSENSITIZING AGENT; THYMIDINE KINASE; TOXIN; VIRUS VECTOR;

ANTIGEN PRESENTATION; APOPTOSIS; CANCER THERAPY; CHEMOSENSITIVITY; DENDRITIC CELL; EFFECTOR CELL; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOPOTENTIATION; METASTASIS; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SUICIDE GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNE TOLERANCE; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033152628     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00061-1     Document Type: Review

References (185)

1. Weinberg R.A. How cancer arises. Scientific American. 275:1996;62-70.
2. Cancer Genome Anatomy Project (CGAP). National Institutes of Health. http://www.ncbi.nlm.nih.gov/ncicgap/.
3. Anderson W.F. Human gene therapy. Nature. 392:1998;25-30.
4. Blau H., Springer M.L. Gene therapy - a novel form of drug delivery. New Engl. J. Med. 333:1995;1204-1207.
5. Roth J.A., Cristiano R.J. Gene therapy for cancer: what have we done and where are we going? J. Nat. Cancer Inst. 89:1997;21-39.
6. Nielsen L.L., Maneval D.C. p53 tumor suppressor gene therapy for cancer. Cancer Gene Therapy. 5:1998;52-63.
7. Orr R.M., Monia B.P. Antisense therapy for cancer. Curr. Res. Mol. Therapeutics. 1:1998;102-108.
8. Deshane J., Loechel F., Conry R.M., Siegal G.P., King C.R., Curiel D.T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy. 1:1994;332-337.
9. Deshane J., Cabrera G., Grim J.E.et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecologic Oncol. 59:1995;8-14.
10. Denekamp J., Dasu A., Waites A. Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Advances in Enzyme Regulation. 38:1998;281-299.
11. Bicknell R. Vascular targeting and the inhibition of angiogenesis. Ann. Oncol. 5(Suppl. 4):1994;45-50.
12. Burrows F.J., Thorpe P.E. Vascular targeting - a new approach to the therapy of solid tumors. Pharmacology and Therapeutics. 64:1994;155-174.
13. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 13:1991;31-36.
14. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
15. Kakeji Y., Teicher B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Investigational New Drugs. 15:1997;39-48.
16. Gradishar W.J. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Investigational New Drugs. 15:1997;49-59.
17. Kong H.L., Crystal R.G. Gene therapy strategies for tumor antiangiogenesis. J. Nat. Cancer Inst. 90:1998;273-286.
18. Folkman J. Antiangiogenic gene therapy. Proc. Nat. Acad. Sci. U.S.A. 95:1998;9064-9066.
19. Saleh M., Stacker S.A., Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56:1996;393-401.
20. Cheng S.Y., Huang H.J., Nagane M.et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Nat. Acad. Sci. USA. 93:1996;8502-8507.
21. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:1994;576-579.
22. Millauer B., Longhi M.P., Plate K.H.et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620.
23. Goldman C.K., Kendall R.L., Cabrera G.et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Nat. Acad. Sci. U.S.A. 95:1998;8795-8800.
24. Kong H.L., Hecht D., Song W.et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Human Gene Therapy. 9:1998;823-833.
25. Lin P., Buxton J.A., Acheson A.et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Nat. Acad. Sci. USA. 95:1998;8829-8834.
26. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54:1994;6504-6511.
27. Tanaka T., Manome Y., Wen P., Kufe D.W., Fine H.A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Medicine. 3:1997;437-442.
28. Tanaka T., Cao Y., Folkman J., Fine H.A. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58:1998;3362-3369.
29. Griscelli F., Li H., Bennaceur-Griscelli A.et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Nat. Acad. Sci. USA. 95:1998;6367-6372.
30. Nabel E.G., Plautz G., Nabel G.J. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc. Nat. Acad. Sci. USA. 89:1992;5157-5161.
31. Tanaka T. Effect of adenoviral-mediated thymidine kinase transduction and ganciclovir therapy on tumor-associated endothelial cells. Neurologia Medico-Chirurgica (Tokyo). 37:1997;730-737.
32. Huang Y.W., Baluna R., Vitetta E.S. Adhesion molecules as targets for cancer therapy. Histology and Histopathology. 12:1997;467-477.
33. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
34. Sumantran V.N., Ealovega M.W., Nunez G., Clarke M.F., Wicha M.S. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55:1995;2507-2510.
35. Weller M., Malipiero U., Rensing-Ehl A., Barr P.J., Fontana A. Fas/Apo-1 gene transfer for human malignant glioma. Cancer Res. 55:1995;2936-2944.
36. Mackey T.J., Borkowski A., Amin P., Jacobs S.C., Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 52:1998;1085-1090.
37. Harima Y., Harima K., Shikata N., Oka A., Ohnishi T., Tanaka Y. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J. Cancer Res. and Clin. Oncol. 124:1998;503-510.
38. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
39. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
40. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
41. Sinkovics J., Horvath J. Apoptosis by genetic engineering. Leukemia. 8(Suppl. 1):1994;S98-102.
42. Neubauer A., Thiede C., Huhn D., Wittig B. P53 and induction of apoptosis as a target for anticancer therapy. Leukemia. 10(Suppl. 3):1996;S2-S4.
43. Favrot M., Coll J.L., Louis N., Negoescu A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Therapy. 5:1998;728-739.
44. Moolten F.L. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Therapy. 1:1994;279-287.
45. Deonarain M.P., Spooner R.A., Epenetos A.A. Genetic delivery of enzymes for cancer therapy. Gene Therapy. 2:1995;235-244.
46. Freeman S.M., Whartenby K.A., Freeman J.L., Abboud C.N., Marrogi A.J. In situ use of suicide genes for cancer therapy. Semin. Oncol. 23:1996;31-45.
47. Martin L.A., Lemoine N.R. Direct cell killing by suicide genes. Cancer and Metastasis Reviews. 15:1996;301-316.
48. Rigg A., Sikora K. Genetic prodrug activation therapy. Mol. Med. Today. 3:1997;359-366.
49. Niculescu-Duvaz I., Spooner R., Marais R., Springer C.J. Gene-directed enzyme prodrug therapy. Bioconjugate Chemistry. 9:1998;4-22.
50. Moolten F.L., Wells J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Nat. Cancer Inst. 82:1990;297-300.
51. Brand K., Arnold W., Bartels T.et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Therapy. 4:1997;9-16.
52. van der Eb M.M., Cramer S.J., Vergouwe Y.et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy. 5:1998;451-458.
53. Culver K.W., Link C.J., Akdemir N., Blaese R.M. In vivo gene transfer of the herpes simplex-thymidine kinase (hs-tk) gene for the treatment of solid tumors (Meeting Abstract). Proc. Ann. M. Am. Soc. Clin. Oncol. 12:1993;A286.
54. Takamiya Y., Short M.P., Ezzeddine Z.D., Moolten F.L., Breakefield X.O., Martuza R.L. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosciences Res. 33:1992;493-503.
55. Freeman S.M., Abboud C.N., Whartenby K.A.et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274.
56. Pope I.M., Poston G.J., Kinsella A.R. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer. 33:1997;1005-1016.
57. Rosenfeld M.E., Feng M., Michael S.I., Siegal G.P., Alvarez R.D., Curiel D.T. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res. 1:1995;1571-1580.
58. Alvarez R.D., Curiel D.T. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Human Gene Therapy. 8:1997;597-613.
59. Bridgewater J.A., Springer C.J., Knox R.J., Minton N.P., Michael N.P., Collins M.K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer. 31A:1995;2362-2370.
60. Blackburn R.V., Galoforo S.S., Corry P.M., Lee Y.J. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. 58:1998;1358-1362.
61. Rogulski K.R., Kim J.H., Kim S.H., Freytag S.O. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Human Gene Therapy. 8:1997;73-85.
62. Aghi M., Kramm C.M., Chou T.C., Breakefield X.O., Chiocca E.A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Nat. Cancer Inst. 90:1998;370-380.
63. Sorrentino B.P., Brandt S.J., Bodine D.et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 257:1992;99-103.
64. Rafferty J.A., Hickson I., Chinnasamy N.et al. Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer and Metastasis Reviews. 15:1996;365-383.
65. Deisseroth A.B., Holmes F., Hortobagyi G., Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Human Gene Therapy. 7:1996;401-416.
66. Dorigo O., Turla S.T., Lebedeva S., Gjerset R.A. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J. Neurosurgery. 88:1998;535-540.
67. Piche A., Grim J., Rancourt C., Gomez-Navarro J., Reed J.C., Curiel D.T. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:1998;2134-2140.
68. Barnes M.N., Deshane J.S., Siegal G.P., Alvarez R.D., Curiel D.T. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin. Cancer Res. 2:1996;1089-1095.
69. Chen L., Waxman D.J., Chen D., Kufe D.W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56:1996;1331-1340.
70. Pederson L.C., Buchsbaum D.J., Vickers S.M.et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 57:1997;4325-4332.
71. Sterman D.H., Treat J., Litzky L.A.et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Human Gene Therapy. 9:1998;1083-1092.
72. Yee D., McGuire S.E., Brunner N.et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Human Gene Therapy. 7:1996;1251-1257.
73. Burnett F.M. The concept of immunological surveillance. Prog. Exper. Tumor Res. 13:1970;1-27.
74. Tuting T., Storkus W.J., Lotze M.T. Gene-based strategies for the immunotherapy of cancer. J. Mol. Med. 75:1997;478-491.
75. Rosenberg S.A., Aebersold P., Cornetta K.et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New Engl. J. Med. 323:1990;570-578.
76. Hwu P., Rosenberg S.A. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detection & Prevention. 18:1994;43-50.
77. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunotherapy. 45:1997;131-136.
78. Hodi F.S., Dranoff G. Genetically modified tumor cell vaccines. Surgical Oncology Clinics of North America. 7:1998;471-485.
79. Hellstrom I., Hellstrom K.E. Tumor vaccines - a reality at last? J. Immunotherapy. 21:1998;119-126.
80. Mastrangelo M.J., Sato T., Lattime E.C., Maguire H.C.J., Berd D. Cellular vaccine therapies for cancer. Cancer Treat. and Res. 94:1998;35-50.
81. Pardoll D.M. Cancer vaccines. Nature Medicine. 4:1998;525-531.
82. Hersh E.M., Stopeck A.T. Advanced in the biological therapy and gene therapy of malignant disease. Clin. Cancer Res. 3:1997;2623-2629.
83. Morel A., de La Coste A., Fernandez N.et al. Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice? Cancer Gene Therapy. 5:1998;92-100.
84. Fenton R.G., Longo D.L. Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J. Nat. Cancer Inst. 89:1997;272-275.
85. Staveley-O'Carroll K., Sotomayor E., Montgomery J.et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Nat. Acad. Sci. USA. 95:1998;1178-1183.
86. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunotherapy. 20:1997;165-177.
87. Ellem K.A., Schmidt C.W., Li C.L.et al. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: "how do I lose thee? Let me count the ways" Adv. Cancer Res. 75:1998;203-249.
88. Orkin SH, Motulsky AG. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http://www.nih.gov/od/orda/panelrep.htm.
89. Russell S.J. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur. J. Cancer. 30A:1994;1165-1171.
90. Miller R., Curiel D.T. Towards the use of replicative adenoviral vectors for cancer gene therapy. Gene Therapy. 3:1996;557-559.
91. Bilbao G., Feng M., Rancourt C., Jackson W.H.J., Curiel D.T. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J. 11:1997;624-634.
92. Kirn D.H., McCormick F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today. 2:1996;519-527.
93. Pennisi E. Training viruses to attack cancers. Science. 282:1998;1244-1246.
94. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:1997;2559-2563.
95. Bischoff J.R., Kirn D.H., Williams A.et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
96. Kirn D., Hermiston T., McCormick F. ONYX-015: clinical data are encouraging (letter). Nature Med. 4:1998;1341-1342.
97. Goodrum F.D., Ornelles D.A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:1998;9479-9490.
98. Rothmann T., Hengstermann A., Whitaker N.J., Scheffner M., zur H.H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:1998;9470-9478.
99. Kramm C.M., Chase M., Herrlinger U.et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Human Gene Therapy. 8:1997;2057-2068.
100. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W. Reovirus therapy of tumors with activated Ras pathway. Science. 282:1998;1332-1334.
101. Dmitriev I., Krasnykh V., Miller C.R.et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:1998;9706-9713.
102. Freytag S.O., Rogulski K.R., Paielli D.L.et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Human Gene Therapy. 9:1998;1323-1333.
103. Bilbao G., Contreras J.L., Gomez-Navarro J., Curiel D.T. Improving adenoviral vectors for cancer gene therapy. Tumor Targeting. 3:1998;59-79.
104. Rancourt C., Piche A., Gomez-Navarro J.et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clin. Cancer Res. 5:1999;43-50.
105. Dion L.D., Goldsmith K.T., Garver Jr R.I. Quantitative and in vivo activity of adenoviral-producing cells made by cotransduction of a replication-defective adenovirus and a replication-enabling plasmid. Cancer Gene Therapy. 3:1996;230-237.
106. Gomez-Navarro J., Rancourt C., Wang M.H.et al. Transcomplementation of a replication-incompetent adenovirus expressing herpes simplex virus thymidine kinase in ovarian carcinoma cells produces progeny virus capable of killing after treatment with ganciclovir. Tumor Targeting. 3:1998;169-177.
107. Feng M., Jackson W.H.J., Goldman C.K.et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnology. 15:1997;866-870.
108. Ramsey W.J., Caplen N.J., Li Q., Higginbotham J.N., Shah M., Blaese R.M. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors. Biochemical and Biophysical Research Communications. 246:1998;912-919.
109. Vile R.G. A marriage of viral vectors. Nature Biotechnology. 15:1997;840-841.
110. Kafri T., van Praag H., Ouyang L., Gage F.H., Verma I.M. A packaging cell line for Lentivirus Vectors. J. Virol. 73:1999;576-584.
111. Miyoshi H., Blomer U., Takahashi M., Gage F.H., Verma I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72:1998;8150-8157.
112. Zufferey R., Dull T., Mandel R.J.et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:1998;9873-9880.
113. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology. 15:1997;871-875.
114. Gahery-Segard H., Farace F., Godfrin D.et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72:1998;2388-2397.
115. Zinkernagel R.M., Hengartner H. Antiviral immunity. Immunology Today. 18:1997;258-260.
116. Worgall S., Wolff G., Falck-Pedersen E., Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Human Gene Therapy. 8:1997;37-44.
117. Lieber A., He C.Y., Meuse L., Himeda C., Wilson C., Kay M.A. Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. J. Virol. 72:1998;9267-9277.
118. Morsy M.A., Caskey C.T. Expanded-capacity adenoviral vectors - the helper-dependent vectors. Mol. Med. Today. 5:1999;18-24.
119. Ploegh H.L. Viral strategies of immune evasion. Science. 280:1998;248-253.
120. Qin L., Ding Y., Pahud D.R., Robson N.D., Shaked A., Bromberg J.S. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Human Gene Therapy. 8:1997;1365-1374.
121. Zhang H.G., Zhou T., Yang P., Edwards C.K., Curiel D.T., Mountz J.D. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Human Gene Therapy. 9:1998;1875-1884.
122. Ilan Y., Attavar P., Takahashi M.et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J. Clin. Investigation. 98:1996;2640-2647.
123. Ilan Y., Sauter B., Chowdhury N.R.et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology. 27:1998;1368-1376.
124. Zhang H.G., Liu D., Heike Y.et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nature Biotechnology. 16:1998;1045-1049.
125. Douglas J.T., Curiel D.T. Targeted adenoviral vectors for cancer gene therapy. Int. J. Oncol. 11:1997;341-348.
126. Chen L., Chen D., Manome Y., Dong Y., Fine H.A., Kufe D.W. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96:1995;2775-2782.
127. Chen S.H., Shine H.D., Goodman J.C., Grossman R.G., Woo S.L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo (meeting abstract). Proc. Ann. Meeting Am. Ass. Cancer Res. 35:1994;A2504.
128. Hwang H.C., Smythe W.R., Elshami A.A.et al. Gene therapy using adenovirus carrying the herpes simplex- thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Resp. Cell and Mol. Biol. 13:1995;7-16.
129. Rosenfeld M.E., Wang M., Siegal G.P.et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med. 74:1996;455-462.
130. Miller C.R., Buchsbaum D.J., Reynolds P.N.et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58:1998;5738-5748.
131. Douglas J.T., Curiel D.T. Targeted gene therapy. Tumor Targeting. 1:1995;67-84.
132. Bergelson J.M., Cunningham J.A., Droguett G.et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997;1320-1323.
133. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Nat. Acad. Sci. USA. 94:1997;3352-3356.
134. Henry L.J., Xia D., Wilke M.E., Deisenhofer J., Gerard R.D. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J. Virol. 68:1994;5239-5246.
135. Louis N., Fender P., Barge A., Kitts P., Chroboczek J. Cell-binding domain of adenovirus serotype 2 fiber. J. Virol. 68:1994;4104-4106.
136. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 73:1993;309-319.
137. Bai M., Harfe B., Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J. Virol. 67:1993;5198-5205.
138. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnology. 14:1996;1574-1578.
139. Goldman C.K., Rogers B.E., Douglas J.T.et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57:1997;1447-1451.
140. Miller C.R., Buchsbaum D.J., Reynolds P.N.et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58:1998;5738-5748.
141. Rancourt C., Rogers B.E., Sosnowski B.A.et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4:1998;2455-2461.
142. Reynolds P.N., Miller C.R., Goldman C.K.et al. Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells. Tumor Targeting. 3:1998;156-168.
143. Rogers B.E., Douglas J.T., Sosnowski B.A.et al. Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropsim-modified adenovirus vector. Tumor Targeting. 3:1998;25-31.
144. Rogers B.E., Douglas J.T., Ahlem C., Buchsbaum D.J., Frincke J., Curiel D.T. Use of a novel cross-linking method to modify adenovirus tropism. Gene Therapy. 4:1997;1387-1392.
145. Wickham T.J., Segal D.M., Roelvink P.W.et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70:1996;6831-6838.
146. Wickham T.J., Lee G.M., Titus J.A.et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol. 71:1997;7663-7669.
147. Yoshida Y., Sadata A., Zhang W., Saito K., Shinoura N., Hamada H. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Human Gene Therapy. 9:1998;2503-2515.
148. Michael S.I., Hong J.S., Curiel D.T., Engler J.A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Therapy. 2:1995;660-668.
149. Wickham T.J., Tzeng E., Shears L.L.et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71:1997;8221-8229.
150. Wickham T.J., Roelvink P.W., Brough D.E., Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature Biotechnology. 14:1996;1570-1573.
151. Krasnykh V., Dmitriev I., Mikheeva G., Miller C.R., Belousova N., Curiel D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. Journal of Virology. 72:1998;1844-1852.
152. Douglas JT, Miller CR, Kim M, et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. 1999, in press.
153. Cosset F.L., Russell S.J. Targeting retrovirus entry. Gene Therapy. 3:1996;946-956.
154. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 380:1996;364-366.
155. Barry M.A., Dower W.J., Johnston S.A. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nature Medicine. 2:1996;299-305.
156. Kanai F., Lan K.H., Shiratori Y.et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Research. 57:1997;461-465.
157. Wills K.N., Huang W.M., Harris M.P., Machemer T., Maneval D.C., Gregory R.J. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Therapy. 2:1995;191-197.
158. Kochanek S., Clemens P.R., Mitani K., Chen H.H., Chan S., Caskey C.T. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Nat. Acad. Sci. U.S.A. 93:1996;5731-5736.
159. Marconi P., Krisky D., Oligino T.et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Nat. Acad. Sci. USA. 93:1996;11319-11320.
160. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Research. 58:1998;1408-1416.
161. Varley A.W., Munford R.S. Physiologically responsive gene therapy. Mol. Med. Today. 4:1998;445-451.
162. Lemmon M.J., Elwell J.H., Brehm J.K.et al. Anaerobic bacteria as a gene delivery system to tumors (meeting abstract). Proc. Ann. Meeting Am. Ass. Cancer Res. 35:1994;A2231.
163. Danthinne X., Aoki K., Kurachi A.L., Nabel G.J., Nabel E.G. Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity. J. Virol. 72:1998;9201-9207.
164. Park J.Y., Elshami A.A., Amin K., Rizk N., Kaiser L.R., Albelda S.M. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Therapy. 4:1997;909-917.
165. Touraine R.L., Vahanian N., Ramsey W.J., Blaese R.M. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Human Gene Therapy. 9:1998;2385-2391.
166. Asahara T., Murohara T., Sullivan A.et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967.
167. Shi Q., Rafii S., Wu M.H.et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 92:1998;362-367.
168. Peirone M., Ross C.J., Hortelano G., Brash J.L., Chang P.L. Encapsulation of various recombinant mammalian cell types in different alginate microcapsules. J. Biomed. Mat. Res. 42:1998;587-596.
169. Tuting T., Storkus W.J., Lotze M.T. Gene-based strategies for the immunotherapy of cancer. J. Mol. Med. 75:1997;478-491.
170. Brenner M.K., Heslop H.E., Rooney C.M. Gene and cell transfer for specific immunotherapy. Vox Sanginis. 74(Suppl. 2):1998;87-90.
171. Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 12:1994;991-1045.
172. Matzinger P. An innate sense of danger. Semin. Immunol. 10:1998;399-415.
173. Conry R.M., LoBuglio A.F., Curiel D.T. Polynucleotide-mediated immunization therapy of cancer. Semin. Oncol. 23:1996;135-147.
174. Conry R.M., White S.A., Fultz P.N.et al. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin. Cancer Res. 4:1998;2903-2912.
175. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183-1187.
176. Colaco C.A.L.S. Why are dendritic cells central to cancer immunotherapy? Mol. Med. Today. 5:1999;14-17.
177. Nestle F.O., Alijagic S., Gilliet M.et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine. 4:1998;328-332.
178. Fernandez N., Duffour M.T., Perricaudet M., Lotze M.T., Tursz T., Zitvogel L. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines, Cellular and Molecular Therapy. 4:1998;53-65.
179. Gilboa E., Nair S.K., Lyerly H.K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunology and Immunotherapy. 46:1998;82-87.
180. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine. 3:1997;558-561.
181. Gong J., Chen D., Kashiwaba M.et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Nat. Acad. Sci. USA. 95:1998;6279-6283.
182. Wick M., Dubey P., Koeppen H.et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exper. Med. 186:1997;229-238.
183. Bohm W., Schirmbeck R., Reimann J. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection. Cancer Immunol. and Immunotherapy. 44:1997;230-238.
184. Fioretti F., Fradelizi D., Stoppacciaro A.et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol. 161:1998;342-346.
185. Tzai T.S., Lin C.I., Shiau A.L., Wu C.L. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res. 18:1998;1585-1589.